Biotech

All Articles

AstraZeneca posts records on in-house competitors to AbbVie, Pfizer ADCs

.AstraZeneca has actually shared a very early take a look at the performance of its in-house antibod...

iTeos- GSK's TIGIT star reveals meaningful remodeling

.After revealing a stage 3 launch based on favorable midstage outcomes, iTeos as well as GSK are fin...

More collaborative FDA may accelerate unusual illness R&ampD: report

.The FDA must be extra available and also collaborative to release a rise in commendations of unusua...

Zenas, MBX, Bicara head to Nasdaq in warm day for biotech IPOs

.It is actually an unusually occupied Friday for biotech IPOs, with Zenas BioPharma, MBX and also Bi...

Atea's COVID antiviral falls short to stop hospitalizations in stage 3

.Atea Pharmaceuticals' antiviral has stopped working yet another COVID-19 trial, but the biotech sti...

Neurocrine's offer to conserve schizophrenia possibility neglects

.Neurocrine Biosciences' mental illness system pivot has failed. The biotech was incapable to duplic...

Sanofi pays for $110M upfront for late-stage radioligand treatment

.Sanofi has made a late entry to the radioligand gathering, spending 100 thousand euros ($ 110 milli...

F 2G rears $100M for second attempt to acquire new antifungal to market

.After F2G's initial try to get a brand-new training class of antifungal to market was derailed by t...

Moderna targets $1.1 B in R&ampD investing cuts, falls 5 plans among productivity tensions

.Moderna has pledged to cut R&ampD costs by $1.1 billion by 2027. The selection to retract the finan...

Sanofi's $80M bet on Key dystrophy medication finishes in period 3 fail

.Merely four months after Sanofi wager $80 million in upfront cash money on Pivot Therapies' losmapi...